Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

867 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Germline alterations among Hispanic men with prostate cancer.
Pan E, Shaya J, Madlensky L, Randall JM, Javier-Desloges J, Millard FE, Rose B, Parsons JK, Nielsen SM, Hatchell KE, Esplin ED, Nussbaum RL, Weise N, Murphy J, Martinez ME, McKay RR. Pan E, et al. Among authors: rose b. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):599. doi: 10.1038/s41391-022-00539-0. Prostate Cancer Prostatic Dis. 2022. PMID: 35488122 No abstract available.
Germline alterations among Hispanic men with prostate cancer.
Pan E, Shaya J, Madlensky L, Randall JM, Javier-Desloges J, Millard FE, Rose B, Parsons JK, Nielsen SM, Hatchell KE, Esplin ED, Nussbaum RL, Weise N, Murphy J, Martinez ME, McKay RR. Pan E, et al. Among authors: rose b. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):561-567. doi: 10.1038/s41391-022-00517-6. Epub 2022 Feb 28. Prostate Cancer Prostatic Dis. 2022. PMID: 35228665
Analysis of CDK12 alterations in a pan-cancer database.
Pan E, Cabal A, Javier-DesLoges J, Patel D, Panian J, Lee S, Shaya J, Nonato T, Xu X, Stewart T, Rose B, Shabaik A, Cohen E, Kurzrock R, Tamayo P, McKay RR. Pan E, et al. Among authors: rose b. Cancer Med. 2022 Feb;11(3):753-763. doi: 10.1002/cam4.4483. Epub 2021 Dec 12. Cancer Med. 2022. PMID: 34898046 Free PMC article.
Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK, D'Amico AV, Nguyen PL, Einck JP, Kane CJ, McKay RR, Simpson DR, Mundt AJ, Murphy JD, Rose BS. Bryant AK, et al. Cancer. 2018 Jul 15;124(14):2939-2947. doi: 10.1002/cncr.31400. Epub 2018 May 4. Cancer. 2018. PMID: 29727915 Free article.
867 results